Zsolt Balázs

University of Zurich — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.4kcitations197works1.82yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(78), Computational Drug Discovery Methods(27), Immunotherapy and Immune Responses(16), Cytomegalovirus and herpesvirus research(14), RNA regulation and disease(14)

Publications197 total

Uncovering Cas9 PAM diversity through metagenomic mining and machine learning

Universität Zürich, ZORA·2026Open Access

Uncovering Cas9 PAM diversity through metagenomic mining and machine learning

Nature Communications·2026Open Access

Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S11 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

page 1 of 10Next →

Frequent Co-authors

Zsolt Boldogkői(25), Dóra Tombácz(25), Michael Krauthammer(24), M Snyder(21), Zsolt Csabai(19), Norbert Moldován(16), Aizhan Tastanova(15), Mitchell P. Levesque(14), Patrick Turko(13), Reinhard Dummer(12), Attila Szűcs(10), Ossia M. Eichhoff(10), Corinne I. Stoffel(10), Jan Käsler(10), Luzia Briker(10), Gergely Karsai(10), Nina Zila(10), Verena Paulitschke(10), Phil F. Cheng(10), Alexander Leitner(10)